Overview: FISH SRY Gene Panel
Introduction: The FISH SRY Gene Panel is a diagnostic tool designed to confirm sex determination using whole blood samples. In India, disorders of sex development (DSD) including 46,XY gonadal dysgenesis or 46,XX testicular DSD are rare but underdiagnosed (~1 in 5,000â€"10,000 births), with SRY gene detection essential for diagnosis in sex reversal cases. High morbidity from underdiagnosis in rural/low-SES children with ambiguous genitalia or delayed puberty, limited genetic testing access, delayed hormone therapy or gender assignment leading to psychological distress or infertility. Per cytogenetics practices aligned with ICMR and Indian Society of Human Genetics guidelines, the test employs FISH for SRY gene detection over 1-2 days with high sensitivity/specificity, valuable for rapid confirmation in DSD workup. This diagnostic falls under genetic screening and targets infants/children with ambiguous genitalia or sex reversal suspicion, addressing accurate detection to guide multidisciplinary management and counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise sex chromosome assessment and reducing long-term complications. Its whole blood-based approach ensures reliable SRY detection.
Other Names: FISH SRY Pnl.
FDA Status: FDA approved, CLIA certified for cytogenetics, compliant with 2025 standards.
Historical Milestone: SRY FISH for DSD; in India, used in pediatric endocrinology.
Purpose: The test detects 2 parameters including SRY gene detection to guide sex determination assessment, confirm SRY presence, inform gender management.
Test Parameters: 1. SRY Gene Detection, 2. Chromosomal Analysis.
Pretest Condition: No fasting required; patients should have suspected sex reversal or DSD.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for FISH).
Medical History: Patients should provide details on genital ambiguity, puberty delay, family history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed DSD including gender issues, benefits of confirmation, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using FISH by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided probes/controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low cell count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive SRY indicates 46,XY DSD; absence suggests other etiology, necessitating specialist input.
Specialist Consultation: Pediatric endocrinologists or geneticists should be consulted for management.
Additional Supporting Tests: Karyotype, hormone levels for confirmation.
Test Limitations: Detects SRY only; comprehensive approach required.
References: Indian Journal of Pediatrics 2024, DSD Studies India 2023.
